REFERENCES
1. Liu J, Fang Z, Lu Q, Wang Y, Zhang L. Projecting global trends and inequalities in adult overweight and obesity, 2023-2040: findings from the NCD-RisC database. Obesity. 2025;33:1955-67.
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027-50.
3. Bianchettin RG, Gawey BJ, Acosta AJ, et al. Clinical assessment of people with obesity: focus on adiposity-related multimorbidity. Mayo Clin Proc. 2025;100:1005-29.
4. Xing L, Zhu X, Klomjit N, et al. Human obesity decreases the anti-inflammatory functionality of adipose tissue-derived mesenchymal stem/stomal cells by upregulating IL-1β expression. Stem Cells. 2025;43:sxaf058.
5. Pérez LM, de Lucas B, Gálvez BG. Unhealthy stem cells: when health conditions upset stem cell properties. Cell Physiol Biochem. 2018;46:1999-2016.
6. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
7. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21:2724-52.
8. Mohamed-Ahmed S, Fristad I, Lie SA, et al. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. Stem Cell Res Ther. 2018;9:168.
9. Calcat-I-Cervera S, Rendra E, Scaccia E, et al. Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach. Stem Cell Res Ther. 2023;14:120.
10. Engin AB. Mechanism of obesity-related lipotoxicity and clinical perspective. Adv Exp Med Biol. 2024;1460:131-66.
11. Ulum B, Teker HT, Sarikaya A, et al. Bone marrow mesenchymal stem cell donors with a high body mass index display elevated endoplasmic reticulum stress and are functionally impaired. J Cell Physiol. 2018;233:8429-36.
12. Ly LD, Xu S, Choi SK, et al. Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes. Exp Mol Med. 2017;49:e291.
13. Lu J, Wang Q, Huang L, et al. Palmitate causes endoplasmic reticulum stress and apoptosis in human mesenchymal stem cells: prevention by AMPK activator. Endocrinology. 2012;153:5275-84.
14. Dalla Valle A, Vertongen P, Spruyt D, et al. Induction of stearoyl-CoA 9-desaturase 1 protects human mesenchymal stromal cells against palmitic acid-induced lipotoxicity and inflammation. Front Endocrinol. 2019;10:726.
15. Polat EG, Şeker ME, Pervin B, Ulum B, Aerts-Kaya F. Obesity-induced loss of function of bone marrow mesenchymal stromal cells is linked to cellular stress and irreversible at advanced stages. J Cell Mol Med. 2025;29:e70776.
16. Yaghooti H, Mohammadtaghvaei N, Mahboobnia K. Effects of palmitate and astaxanthin on cell viability and proinflammatory characteristics of mesenchymal stem cells. Int Immunopharmacol. 2019;68:164-70.
17. Yan W, Diao S, Fan Z. The role and mechanism of mitochondrial functions and energy metabolism in the function regulation of the mesenchymal stem cells. Stem Cell Res Ther. 2021;12:140.
18. Eirin A, Thaler R, Glasstetter LM, et al. Obesity-driven mitochondrial dysfunction in human adipose tissue-derived mesenchymal stem/stromal cells involves epigenetic changes. Cell Death Dis. 2024;15:387.
19. Meng Y, Eirin A, Zhu XY, et al. Obesity-induced mitochondrial dysfunction in porcine adipose tissue-derived mesenchymal stem cells. J Cell Physiol. 2018;233:5926-36.
20. de Mello AH, Costa AB, Engel JDG, Rezin GT. Mitochondrial dysfunction in obesity. Life Sci. 2018;192:26-32.
21. Wang B, Zhang G, Hu Y, et al. Uncovering impaired mitochondrial and lysosomal function in adipose-derived stem cells from obese individuals with altered biological activity. Stem Cell Res Ther. 2024;15:12.
22. Pérez LM, Bernal A, de Lucas B, et al. Altered metabolic and stemness capacity of adipose tissue-derived stem cells from obese mouse and human. PLoS One. 2015;10:e0123397.
23. Zheng P, Ma W, Gu Y, et al. High-fat diet causes mitochondrial damage and downregulation of mitofusin-2 and optic atrophy-1 in multiple organs. J Clin Biochem Nutr. 2023;73:61-76.
24. Finocchietto P, Perez H, Blanco G, et al. Inhibition of mitochondrial fission by Drp-1 blockade by short-term leptin and Mdivi-1 treatment improves white adipose tissue abnormalities in obesity and diabetes. Pharmacol Res. 2022;178:106028.
25. Farahani RA, Farah MC, Zhu XY, et al. Metabolic syndrome impairs 3D mitochondrial structure, dynamics, and function in swine mesenchymal stem cells. Stem Cell Rev Rep. 2020;16:933-45.
26. Liu L, Wang Y, Fan H, et al. MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. Stem Cells. 2012;30:1756-70.
27. Indrieri A, Carrella S, Romano A, et al. miR-181a/b downregulation exerts a protective action on mitochondrial disease models. EMBO Mol Med. 2019;11:e8734.
28. Kornicka K, Houston J, Marycz K. Dysfunction of mesenchymal stem cells isolated from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and autophagy may limit their potential therapeutic use. Stem Cell Rev Rep. 2018;14:337-45.
29. Wan W, Zhang L, Lin Y, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023;21:36.
30. Luo YH, Xie L, Li JY, Xie Y, Li MQ, Zhou L. Serum MOTS-C levels are decreased in obese children and associated with vascular endothelial function. Diabetes Metab Syndr Obes. 2023;16:1013-20.
31. Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med. 2018;66:1019-22.
32. Yoon SH, Yuan F, Zhu X, et al. Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. J Clin Transl Endocrinol. 2026;43:100429.
33. Sequeira IR, Woodhead JST, Chan A, et al. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochim Biophys Acta Gen Subj. 2021;1865:129991.
34. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381-400.
35. Marcondes-de-Castro IA, Reis-Barbosa PH, Marinho TS, Aguila MB, Mandarim-de-Lacerda CA. AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression. J Gastroenterol Hepatol. 2023;38:1868-76.
36. Tao Z, Aslam H, Parke J, Sanchez M, Cheng Z. Mechanisms of autophagic responses to altered nutritional status. J Nutr Biochem. 2022;103:108955.
37. Sagar S, Faizan MI, Chaudhary N, et al. Obesity impairs cardiolipin-dependent mitophagy and therapeutic intercellular mitochondrial transfer ability of mesenchymal stem cells. Cell Death Dis. 2023;14:324.
38. Al-Sammarraie SHA, Ayaz-Güner Ş, Acar MB, et al. Mesenchymal stem cells from adipose tissue prone to lose their stemness associated markers in obesity related stress conditions. Sci Rep. 2024;14:19702.
39. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258-62.
40. Choi SE, Fu T, Seok S, et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell. 2013;12:1062-72.
41. Jukarainen S, Heinonen S, Rämö JT, et al. Obesity is associated with low NAD+/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic twins. J Clin Endocrinol Metab. 2016;101:275-83.
42. Afarideh M, Thaler R, Khani F, et al. Global epigenetic alterations of mesenchymal stem cells in obesity: the role of vitamin C reprogramming. Epigenetics. 2021;16:705-17.
43. Xie S, Choudhari S, Wu CL, et al. Aging and obesity prime the methylome and transcriptome of adipose stem cells for disease and dysfunction. FASEB J. 2023;37:e22785.
44. Tryggestad JB, Teague AM, Sparling DP, Jiang S, Chernausek SD. Macrophage-derived microRNA-155 increases in obesity and influences adipocyte metabolism by targeting peroxisome proliferator-activated receptor gamma. Obesity. 2019;27:1856-64.
45. Pan Y, Hui X, Hoo RLC, et al. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. J Clin Invest. 2019;129:834-49.
46. Wang L, Sun M, Cao Y, et al. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload. Arch Biochem Biophys. 2020;695:108642.
47. Briones-Espinoza MJ, Cortés-García JD, Vega-Cárdenas M, et al. Decreased levels and activity of Sirt1 are modulated by increased miR-34a expression in adipose tissue mononuclear cells from subjects with overweight and obesity: a pilot study. Diabetes Metab Syndr. 2020;14:1347-54.
48. Mokhberian N, Bolandi Z, Eftekhary M, et al. Inhibition of miR-34a reduces cellular senescence in human adipose tissue-derived mesenchymal stem cells through the activation of SIRT1. Life Sci. 2020;257:118055.
49. Karkeni E, Astier J, Tourniaire F, et al. Obesity-associated inflammation induces microRNA-155 expression in adipocytes and adipose tissue: outcome on adipocyte function. J Clin Endocrinol Metab. 2016;101:1615-26.
50. Onodera Y, Teramura T, Takehara T, Obora K, Mori T, Fukuda K. miR-155 induces ROS generation through downregulation of antioxidation-related genes in mesenchymal stem cells. Aging Cell. 2017;16:1369-80.
51. Bispo AFS, de Jesus Simao J, Moraes MA, et al. Effects of obesity-associated plasma markers on adipose stem cell function and epigenetic regulation. Obesity. 2025;33:1529-42.
52. Grun LK, Maurmann RM, Scholl JN, et al. Obesity drives adipose-derived stem cells into a senescent and dysfunctional phenotype associated with P38MAPK/NF-KB axis. Immun Ageing. 2023;20:51.
53. Kang Q, Zhu X, Ren D, et al. Adipose METTL14-elicited N6-methyladenosine promotes obesity, insulin resistance, and NAFLD through suppressing β adrenergic signaling and lipolysis. Adv Sci. 2023;10:e2301645.
54. Wang X, Wu R, Liu Y, et al. m6A mRNA methylation controls autophagy and adipogenesis by targeting Atg5 and Atg7. Autophagy. 2020;16:1221-35.
55. Wu Y, Xie L, Wang M, et al. Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun. 2018;9:4772.
56. He M, Lei H, He X, et al. METTL14 regulates osteogenesis of bone marrow mesenchymal stem cells via inducing autophagy through m6A/IGF2BPs/Beclin-1 signal axis. Stem Cells Transl Med. 2022;11:987-1001.
57. Hinte LC, Castellano-Castillo D, Ghosh A, et al. Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature. 2024;636:457-65.
58. Silva KR, Liechocki S, Carneiro JR, et al. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery ex-obese women. Stem Cell Res Ther. 2015;6:72.
59. Adnan A, Juntunen M, Tyrväinen T, et al. Effects of bariatric surgery-related weight loss on the characteristics, metabolism, and immunomodulation of adipose stromal/stem cells in a follow-up study. Stem Cells Int. 2025;2025:1212255.
60. Miranda AMA, McAllan L, Mazzei G, et al. Selective remodelling of the adipose niche in obesity and weight loss. Nature. 2025;644:769-79.
61. Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018;9:63.
62. Welsh JA, Goberdhan DCI, O’Driscoll L, et al.; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
63. Togliatto G, Dentelli P, Gili M, et al. Obesity reduces the pro-angiogenic potential of adipose tissue stem cell-derived extracellular vesicles (EVs) by impairing miR-126 content: impact on clinical applications. Int J Obes. 2016;40:102-11.
64. Eirin A, Meng Y, Zhu XY, et al. The micro-RNA cargo of extracellular vesicles released by human adipose tissue-derived mesenchymal stem cells is modified by obesity. Front Cell Dev Biol. 2021;9:660851.
65. Conley SM, Shook JE, Zhu XY, et al. Metabolic syndrome induces release of smaller extracellular vesicles from porcine mesenchymal stem cells. Cell Transplant. 2019;28:1271-8.
66. Eirin A, Ferguson CM, Zhu XY, et al. Extracellular vesicles released by adipose tissue-derived mesenchymal stromal/stem cells from obese pigs fail to repair the injured kidney. Stem Cell Res. 2020;47:101877.
67. Conley SM, Hickson LJ, Kellogg TA, et al. Human obesity induces dysfunction and early senescence in adipose tissue-derived mesenchymal stromal/stem cells. Front Cell Dev Biol. 2020;8:197.
68. Zhu Z, Gan X, Yu H. NF‑κB‑miR15a‑bFGF/VEGFA axis contributes to the impaired angiogenic capacity of BM‑MSCs in high fat diet‑fed mice. Mol Med Rep. 2017;16:7609-16.
69. Serena C, Keiran N, Ceperuelo-Mallafre V, et al. Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells. Stem Cells. 2016;34:2559-73.
70. Acar MB, Ayaz-Güner Ş, Di Bernardo G, et al. Obesity induced by high-fat diet is associated with critical changes in biological and molecular functions of mesenchymal stromal cells present in visceral adipose tissue. Aging. 2020;12:24894-913.
71. Klomjit N, Conley SM, Zhu XY, et al. Effects of obesity on reparative function of human adipose tissue-derived mesenchymal stem cells on ischemic murine kidneys. Int J Obes. 2022;46:1222-33.
72. Farahani RA, Zhu XY, Tang H, et al. Metabolic syndrome alters the cargo of mitochondria-related microRNAs in swine mesenchymal stem cell-derived extracellular vesicles, impairing their capacity to repair the stenotic kidney. Stem Cells Int. 2020;2020:8845635.
73. Yu S, Klomjit N, Jiang K, et al. Human obesity attenuates cardioprotection conferred by adipose tissue-derived mesenchymal stem/stromal cells. J Cardiovasc Transl Res. 2023;16:221-32.
74. Hong S, Huang W, Zhu X, et al. Obesity blunts amelioration of cardiac hypertrophy and fibrosis by human mesenchymal stem/stromal cell-derived extracellular vesicles. Am J Physiol Heart Circ Physiol. 2023;325:H163-71.
75. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-50.
76. Yao S, Cen Y, Lou G, Liu Y. Therapeutic potentials of mesenchymal stem cells and their extracellular vesicles on liver diseases by modulating mitochondrial function of macrophages. Int Immunopharmacol. 2025;165:115486.
77. Cen Y, Lou G, Qi J, Zheng M, Liu Y. A new perspective on mesenchymal stem cell-based therapy for liver diseases: restoring mitochondrial function. Cell Commun Signal. 2023;21:214.
78. Shree N, Venkategowda S, Venkatranganna MV, Datta I, Bhonde RR. Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation. Int J Obes. 2019;43:2107-18.
79. Shen Z, Tang X, Zhang Y, et al. Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis. Stem Cells Transl Med. 2024;13:886-97.
80. Chen C, Peng C, Hu Z, Ge L. Effects of bone marrow mesenchymal stromal cells-derived therapies for experimental traumatic brain injury: a meta-analysis. Heliyon. 2024;10:e25050.
81. Kota DJ, Prabhakara KS, Toledano-Furman N, et al. Prostaglandin E2 indicates therapeutic efficacy of mesenchymal stem cells in experimental traumatic brain injury. Stem Cells. 2017;35:1416-30.
82. Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci Lett. 2010;482:235-9.
83. Li J, Tang Y, Cai D. IKKβ/NF-κB disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes. Nat Cell Biol. 2012;14:999-1012.
84. Khalid M, Frommer ML, Abu-Hanna J, et al. Influence of donor obesity on adipose-derived stem cell function and therapeutic efficacy. Cells. 2026;15:946.
85. Liu F, Han R, Nie S, et al. Metformin rejuvenates Nap1l2-impaired immunomodulation of bone marrow mesenchymal stem cells via metabolic reprogramming. Cell Prolif. 2024;57:e13612.
86. Mikłosz A, Nikitiuk BE, Chabowski A. Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: where do we stand? Obes Rev. 2022;23:e13413.
87. Le Pelletier L, Mantecon M, Gorwood J, et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife. 2021;10:e62635.
88. Ouyang Z, Kang D, Li K, et al. DEPTOR exacerbates bone-fat imbalance in osteoporosis by transcriptionally modulating BMSC differentiation. Biomed Pharmacother. 2022;151:113164.
89. Wang H, Sun Y, Pi C, et al. Nicotinamide mononucleotide supplementation improves mitochondrial dysfunction and rescues cellular senescence by NAD+/Sirt3 pathway in mesenchymal stem cells. Int J Mol Sci. 2022;23:14739.
90. Song J, Li J, Yang F, et al. Nicotinamide mononucleotide promotes osteogenesis and reduces adipogenesis by regulating mesenchymal stromal cells via the SIRT1 pathway in aged bone marrow. Cell Death Dis. 2019;10:336.
91. Chinnapaka S, Malekzadeh H, Tirmizi Z, Arellano JA, Ejaz A. Nicotinamide riboside improves stemness of human adipose-derived stem cells and inhibits terminal adipocyte differentiation. Pharmaceuticals. 2023;16:1134.
92. Lopez-Yus M, García-Sobreviela MP, Del Moral-Bergos R, Arbones-Mainar JM. Gene therapy based on mesenchymal stem cells derived from adipose tissue for the treatment of obesity and its metabolic complications. Int J Mol Sci. 2023;24:7468.
93. Palmer AK, Xu M, Zhu Y, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18:e12950.
94. Pham DV, Nguyen TK, Park PH. Adipokines at the crossroads of obesity and mesenchymal stem cell therapy. Exp Mol Med. 2023;55:313-24.
95. Pham DV, Nguyen TK, Nguyen BL, et al. Adiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal cells via glycolytic reprogramming. Acta Pharm Sin B. 2024;14:273-91.
96. Song J, Liu J, Cui C, et al. Mesenchymal stromal cells ameliorate diabetes-induced muscle atrophy through exosomes by enhancing AMPK/ULK1-mediated autophagy. J Cachexia Sarcopenia Muscle. 2023;14:915-29.
97. Wang Y, Fu J, He W, et al. Bone marrow mesenchymal stem cells ameliorate diet-induced obesity by activating thermogenesis and alleviating inflammation in adipose tissue. Biochem Biophys Res Commun. 2025;747:151172.
98. Kashbour M, Abdelmalik A, Yassin MNA, et al. Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17:189.
99. Mathur A, Taurin S, Alshammary S. The safety and efficacy of mesenchymal stem cells in the treatment of type 2 diabetes - a literature review. Diabetes Metab Syndr Obes. 2023;16:769-77.
100. Mizenko RR, Feaver M, Bozkurt BT, et al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. 2024;13:e12510.
